Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AdGVPEDF.11D · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AdGVPEDF.11D | DRUG | - |
Inclusion Criteria: * Age greater than or equal to 50 years; * Severe neovascular AMD in at least one eye responsible for a best corrected vision of 20/200 or worse in the study eye (if both eyes have neovascular AMD and equal visual acuity scores, the study eye will be determined by the investigat...
AdGVPEDF.11D is an investigational gene therapy being developed for the treatment of macular degeneration, specifically neovascular age-related macular degeneration (AMD). It is administered to patients aged 50 years and older. The drug is currently in clinical development and has not been approved by regulatory authorities.
AdGVPEDF.11D is being developed by Precigen, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol PGEN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for macular degeneration.
AdGVPEDF.11D is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study. The drug remains investigational and is not yet approved for commercial use.
AdGVPEDF.11D has been studied in one completed Phase 1 clinical trial with the identifier NCT00109499. The trial, titled 'Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD),' was conducted in the United States and enrolled patients with macular degeneration.
AdGVPEDF.11D is a specific variant of the AdGVPEDF gene therapy. The '11D' designation distinguishes it from other versions of the therapy. It is being investigated for the treatment of neovascular age-related macular degeneration.